We respond to the critical challenges of healthcare — we create new, we foresee the future, we find solutions. Our mission is to make people healthy, beautiful and happy.
We put our knowledge, experience and passion into this.
- 2014 - 2007
Resolution of the USSR Council of Ministers was signed on the construction of an antibiotic plant in Saransk. 63 years later the Biokhimik plant will become part of the Promomed Group.
Petr Bely and like-minded people established the PROMOMED company.
The first new drug products have been developed and launched: Revocarin and Neosmectin
A new weight loss drug product Reduxin developed by Promomed became available at pharmacies. Within a year it became the top product in this category.
Promomed opened a modern production site at the plant for manufacturing tablets and capsules
Creation of the in-house biotechnological laboratory – Scientific and Production Engineering Center “Antibiotic”.
Promomed obtained the conclusion from the Ministry of Industry and Trade of the Russian Federation on the compliance of manufacturing process at Biokhimik with the requirements of the Good Manufacturing Practice (GMP).
Minister of Health of the Russian Federation Veronika Skvortsova opened a full cycle production of domestic antibiotics of the latest generations at Biokhimik
Promomed launched a laboratory of chemical and pharmaceutical technologies in the Mordovia State University (Saransk) in the framework of cooperation between the University and Biokhimik
Promomed DM LLC has successfully debuted with its bonds on the Moscow Exchange
Biokhimik, Promomed production site, received certification according to Eurasian GMP standards
23 marketing authorizations received, including Salvisar, Drotaverin, Piracetam, Etamsilat, Ibuprofen, Dioxydin.
Promomed acquired the Biokhimik plant. A new story has begun for the oldest pharmaceutical enterprise.
Marketing authorization obtained for: Ketoprofen, Ketorolac, Sumatriptan, Metformin, Troxerutin
Launch of modernized workshops for the production of tablets, ointments and gels.
The substance for innovative antibiotic Vancomycin has been developed
10 marketing authorizations received, including Ambene Bio, Amikacin, Ofloxacin, Ciprofloxacin
Promomed provided support in opening new department at the Ogarev Mordovia State University, which will be involved in studies of synthesis of new antibiotics.
Promomed has put into commercial operation its own solution for managing the traceability of goods movement, including product labeling and aggregation.
10 marketing authorizations received, including antibiotics Moxifloxacin, Levofloxacin, Azithromycin, Doripinem, Vancomycin
The company started its own production of substances by chemical and biological synthesis, sterile drugs in liquid and lyophilised forms
21 marketing authorizations received, including Reduxin Forte, Etoricoxib, Ademetionine, Citicoline, Tranexamic acid, Meloxicam and more
Development and obtaining marketing authorization for Areplivir, a drug recommended by the Russian Ministry of Health for cOVID-19 treatment, which saved hundreds of thousands of lives during the 2020-2021 pandemic
Promomed DM is assigned long-term credit rating ruBBB+ with a stable outlook.
Launch of a full cycle production site for antiviral drugs
10 marketing authorizations received: Ambene Chondro, Amiodarone, Daptomycin, Lidocaine, Linezolid, Lornia, Tolsitol, Phosphocreatine and more
Petr Bely, the founder of the Promomed Group, was awarded the Pirogov Medal for his merits in the production of pharmaceuticals
The long-term credit rating of Promomed DM has been raised to ruA- with a stable outlook
Promomed drug portfolio continues to grow. 19 new marketing authorizations received since the beginning of the year. These include Enoparin, Cefixime, Ampicillin / Sulbactam, Dexketoprofenum, Kombalgin, Dexpanthenol + Chlorhexidine, Kombalgin Ice, Modela
among domestic manufacturers